{
    "pmcid": "9676808",
    "qa_pairs": {
        "What are the advantages of nanobodies over conventional monoclonal antibodies mentioned in the summary?": [
            "Smaller size, stability at high temperatures, ease of production, and ability to bind cryptic epitopes.",
            "Larger size, higher production cost, and limited ability to bind cryptic epitopes.",
            "Increased immunogenicity, reduced stability, and complex production processes.",
            "Lower binding affinity, reduced specificity, and inability to penetrate tissues effectively."
        ],
        "What computational approach was used to screen and select nanobodies from the database of candidates?": [
            "A comprehensive computational immunoinformatics approach.",
            "A basic sequence alignment method.",
            "A random selection process.",
            "A manual curation based on visual inspection."
        ],
        "What is the purpose of the antiviral peptide added to the nanobody-peptide conjugate?": [
            "To block viral entry by targeting the ACE2 receptor.",
            "To enhance the fluorescent properties of the conjugate.",
            "To increase the molecular weight for better stability.",
            "To serve as a marker for easy detection in assays."
        ],
        "What modification was made to the nanobody-peptide conjugate to improve clinical efficacy and reduce rapid renal clearance?": [
            "PEGylation with a 20 kDa maleimide-terminated PEG.",
            "Addition of a fluorescent tag for tracking.",
            "Conjugation with a radioactive isotope.",
            "Incorporation of a sugar moiety for increased solubility."
        ],
        "Which specific region of the SARS-CoV-2 spike protein do the designed nanobodies target?": [
            "The receptor binding domain (RBD).",
            "The nucleocapsid protein.",
            "The membrane protein.",
            "The envelope protein."
        ]
    }
}